ProKidney Corp.
ProKidney Corp., a clinical-stage biotechnology, engages in developing cellular therapy candidates. It is developing Renal Autologous Cell Therapy, an autologous homologous cell admixture that is in a Phase III development program, as well as Phase II cl…
Biotechnology
US, Winston-Salem [HQ]
Ratios
5 Records · Starting from 2019Margins, Growth Rates In %
| Ratio | 2019 | 2020 | 2021 | 2022 | 2023 | |
|---|---|---|---|---|---|---|
| Profitability | ||||||
| Gross Margin | - - | - - | - - | - - | - - | |
| Profit Margin | - - | - - | - - | - - | - - | |
| Operating Margin | - - | - - | - - | - - | - - | |
|
EPS Growth
|
- - | 86.14 | -114.29 | -703.33 | 76.35 | |
| EPS USD | -101.00 | -14.00 | -30.00 | -241.00 | -57.00 | |
| Return on Assets (ROA) | -406.05 | -160.17 | -136.85 | -28.60 | -8.43 | |
| Return on Equity (ROE) | -501.26 | -271.18 | -204.87 | 13.51 | 3.21 | |
| Return on Invested Capital (ROIC) | -113.93 | -234.54 | -195.21 | 14.07 | 14.43 | |
| Solvency | ||||||
| Equity Ratio | - - | - - | - - | - - | - - | |
| Debt/Assets | 5.15 | 9.34 | 3.31 | 0.46 | 1.05 | |
| Debt/Equity | 6.36 | 15.81 | 4.96 | -0.22 | -0.40 | |
| Debt/EBITDA | 77.72 | 11.60 | 36.19 | 338.82 | 37.91 | |
|
Debt/Capitalization
|
5.98 | 13.65 | 4.72 | -0.22 | -0.40 | |
| Long-Term Debt/Capitalization | 5.98 | 11.91 | 3.81 | -0.17 | -0.33 | |
| Interest Debt per Share USD | 0.01 | 0.01 | 0.01 | 0.04 | 0.07 | |
| Debt Growth | - - | 54.36 | -14.43 | 79.84 | 83.95 | |
| Liquidity | ||||||
| Current Ratio | 568.31 | 101.51 | 221.46 | 4,641.95 | 1,494.31 | |
| Quick Ratio | 561.02 | 83.21 | 166.95 | 4,508.89 | 1,455.09 | |
| Cash Ratio | 561.02 | 83.21 | 166.95 | 4,508.89 | 242.23 | |
| Operating Cash Flow Ratio | - - | -400 | -400 | -700 | -300 | |
| Turnover | ||||||
| Inventory Turnover | - - | - - | - - | - - | - - | |
| Receivables Turnover | - - | - - | - - | - - | - - | |
| Payables Turnover | - - | - - | 70.01 | 99.74 | 62.16 | |
|
Asset Turnover
|
- - | - - | - - | - - | - - | |
| Fixed Turnover | - - | - - | - - | - - | - - | |
| Coverage | ||||||
| Interest Coverage | - - | - - | - - | -71,166.05 | -1,262,683.33 | |
| Asset Coverage | 1,500 | 700 | 2,100 | 21,100 | 8,900 | |
| Cash Flow Coverage (CFGR) | -7.60 | -1,615.20 | -3,770.54 | -3,213.38 | -2,040.99 | |
| EBITDA Coverage | - - | - - | - - | -66,900 | -1,236,200 | |
| Dividend Coverage | - - | - - | - - | - - | - - | |
| Time Interest Earned (TIE) | - - | - - | - - | - - | - - | |
| Market Prospects | ||||||
| Dividend Yield | - - | - - | - - | - - | - - | |
| Earnings Yield | -10.03 | -1.42 | -2.99 | -35.09 | -32.29 | |
|
Price/Earnings (P/E)
|
-9.9717 | -70.4892 | -33.4811 | -2.8499 | -3.0972 | |
| Price/Earnings Growth (PEG) | - - | 81.83 | -29.30 | -0.41 | 4.06 | |
|
Price/Book (P/B)
|
4,998.41 | 19,115.12 | 6,859.42 | -38.50 | -9.96 | |
| Price/Tangible Book (P/TB) | 4,998.41 | 19,115.12 | 6,859.42 | -38.50 | -9.96 | |
| Price/Sales (P/S) | - - | - - | - - | - - | - - | |
|
Price/Cash Flow (P/CF)
|
-1,033,640.42 | -7,487.85 | -3,670.75 | -547.63 | -121.96 | |
| Price/Free CF (P/FCF) | -1,016,371.39 | -6,154.37 | -3,327.30 | -534.83 | -88.40 | |
| Price/Operating CF (P/OCF) | -1,033,640.42 | -7,487.85 | -3,670.75 | -547.63 | -121.96 |